 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditions, today announced that restoration of retinal tissue was observed in a patient enrolled in a Phase 12a study of its lead product candidate, OpRegen, a retinal pigment epithelium RPE cell transplant therapy in development for the treatment of dry age-related macular degeneration AMD. This finding supports the view that dry AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable in atrophic end-stage disease patients. Lineage plans to host a live call with two therapeutic area experts Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation: Research for Vision, and Michael S. Ip, M.D., Chief of Vitreoretinal Surgery Service, Doheny Eye Centers, UCLA, on Monday, June 8, 2020 at 4:30 p.m. ET1:30 p.m. PT. Drs. Monés and Ip will discuss these data and other results of treatment with OpRegen. Interested parties can access the call on the Events and Presentations section of Lineages website. 